Adherium announces interim results from the iCare respiratory care program

Adherium announces interim results from the iCare respiratory care program

Adherium has today announced interim results from the iCARE respiratory care program, demonstrating positive clinical outcomes, including breakthrough adherence and patient engagement, whilst using Adherium’s Hailie® Smartinhaler technology.

The iCARE program, conducted in partnership with Intermountain Health and CareCentra, is one of the largest real-world respiratory care studies designed to evaluate how connected technology can improve outcomes for the 70M people in the US, and approximately 700M people living with COPD and asthma worldwide. The study deployed 4,000 Hallie® Smartinhalers® across five Intermountain Health facilities, supporting up to 2,500 COPD and asthma patients. Analysis of approximately 850 patients enrolled in the study is already demonstrating significant improvements in adherence, engagement, and trends towards improved healthcare outcomes for patients.

Adherium Chief Executive Officer, Dawn Bitz, said:
“By generating actionable patient data, including biometrics from Adherium’s Smartinhaler technology, the iCARE study demonstrates breakthrough adherence, unprecedented patient persistence, reduced hospitalisations, and significant potential cost savings. This data lays strong foundations for a scalable, value-based care model with global commercial relevance. We are now on track to close one of the largest historical gaps in respiratory management, unlocking value for patients, providers, payers, and investors alike.”

Read the ASX release: https://lnkd.in/g-KbeQHi